Simon Haroutounian

Simon Haroutounian

Auto-generated profile, based on publicly available information

Simon Haroutounian

Department of Anesthesiology, Washington University School of Medicine, St Louis, MO, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in The Lancet Neurology
Verified
Journal Article
Closed access
NFNanna Brix Finnerup
Nanna Brix Finnerup
NANadine Attal
Nadine Attal
SHSimon Haroutounian
Simon Haroutounian
EMEwan McNicol
Ewan McNicol
RBRalf Baron
Ralf Baron
MWMark Wallace
Mark Wallace

13 January 2016 in Pain
Verified
Journal Article
Open access
NFNanna Brix Finnerup
Nanna Brix Finnerup
SHSimon Haroutounian
Simon Haroutounian
PKPeter Kamerman
Peter Kamerman
RBRalf Baron
Ralf Baron
DBDavid L.H. Bennett
David L.H. Bennett
TJTroels S. Jensen
Troels S. Jensen
The redefinition of neuropathic pain as “pain arising as a direct consequence of a lesion or disease affecting the somatosensory system,” which was suggested by the International Association for the Study of Pain (IASP) Special Interest Group on Neuropathic Pain (NeuPSIG) in 2008, has been widely accepted. In contrast, the proposed grading system of possible, probable, and definite neuropathic pain from 2008 has been used to a lesser extent. Here, we report a citation analysis of the original NeuPSIG grading paper of 2008, followed by an analysis of its use by an expert panel and recommendations for an improved grading system. As of February, 2015, 608 eligible articles in Scopus cited the paper, 414 of which cited the neuropathic pain definition. Of 220 clinical studies citing the paper, 56 had used the grading system. The percentage using the grading system increased from 5% in 2009 to 30% in 2014. Obstacles to a wider use of the grading system were identified, including (1) questions about the relative significance of confirmatory tests, (2) the role of screening tools, and (3) uncertainties about what is considered a neuroanatomically plausible pain distribution. Here, we present a revised grading system with an adjusted order, better reflecting clinical practice, improvements in the specifications, and a word of caution that even the “definite” level of neuropathic pain does not always indicate causality. In addition, we add a table illustrating the area of pain and sensory abnormalities in common neuropathic pain conditions and propose areas for further research.

1 January 2013 in Pain
Verified
Journal Article
Closed access
SHSimon Haroutiunian
Simon Haroutiunian
LNLone Nikolajsen
Lone Nikolajsen
NFNanna Brix Finnerup
Nanna Brix Finnerup
TJTroels Staehelin Jensen
Troels Staehelin Jensen
Persistent postsurgical pain (PPSP) is a frequent and often disabling complication of many surgical procedures. Nerve injury-induced neuropathic pain (NeuP) has repeatedly been proposed as a major cause of PPSP. However, there is a lack of uniformity in NeuP assessment across studies, and the prevalence of NeuP may differ after various surgeries. We performed a systematic search of the PubMed, CENTRAL, and Embase databases and assessed 281 studies that investigated PPSP after 11 types of surgery. The prevalence of PPSP in each surgical group was examined. The prevalence of NeuP was determined by applying the recently published NeuP probability grading system. The prevalence of probable or definite NeuP was high in patients with persistent pain after thoracic and breast surgeries-66% and 68%, respectively. In patients with PPSP after groin hernia repair, the prevalence of NeuP was 31%, and after total hip or knee arthroplasty it was 6%. The results suggest that the prevalence of NeuP among PPSP cases differs in various types of surgery, probably depending on the likelihood of surgical iatrogenic nerve injury. Because of large methodological variability across studies, a more uniform approach is desirable in future studies for evaluating persistent postsurgical NeuP.

21 April 2017 in Current Pain and Headache Reports
Verified
Journal Article
Closed access
PDF file
KMKathleen Meacham
Kathleen Meacham
ASAndrew J. Shepherd
Andrew J. Shepherd
DMDurga Mohapatra
Durga Mohapatra
SHSimon Haroutounian
Simon Haroutounian

5 May 2016 in Pain
Verified
Journal Article
Closed access
RERobert R. Edwards
Robert R. Edwards
RDRobert H. Dworkin
Robert H. Dworkin
DTDennis C. Turk
Dennis C. Turk
MAMartin S. Angst
Martin S. Angst
RDRaymond Dionne
Raymond Dionne
DYDavid Yarnitsky
David Yarnitsky
There is tremendous interpatient variability in the response to analgesic therapy (even for efficacious treatments), which can be the source of great frustration in clinical practice. This has led to calls for “precision medicine” or personalized pain therapeutics (ie, empirically based algorithms that determine the optimal treatments, or treatment combinations, for individual patients) that would presumably improve both the clinical care of patients with pain and the success rates for putative analgesic drugs in phase 2 and 3 clinical trials. However, before implementing this approach, the characteristics of individual patients or subgroups of patients that increase or decrease the response to a specific treatment need to be identified. The challenge is to identify the measurable phenotypic characteristics of patients that are most predictive of individual variation in analgesic treatment outcomes, and the measurement tools that are best suited to evaluate these characteristics. In this article, we present evidence on the most promising of these phenotypic characteristics for use in future research, including psychosocial factors, symptom characteristics, sleep patterns, responses to noxious stimulation, endogenous pain-modulatory processes, and response to pharmacologic challenge. We provide evidence-based recommendations for core phenotyping domains and recommend measures of each domain.

1 July 2014 in Pain
Verified
Journal Article
Closed access
SHSimon Haroutounian
Simon Haroutounian
LNLone Nikolajsen
Lone Nikolajsen
TBThomas F. Bendtsen
Thomas F. Bendtsen
NFNanna Brix Finnerup
Nanna Brix Finnerup
AKAnders D. Kristensen
Anders D. Kristensen
TJTroels S. Jensen
Troels S. Jensen
Central sensitization after peripheral nerve injury may result in ectopic neuronal activity in the spinal cord dorsal horn, implying a potential autonomous pain-generating mechanism. This study used peripheral nerve blockade and systemic lidocaine administration, with detailed somatosensory assessment, to determine the contribution of primary afferent input in maintaining peripheral neuropathic pain. Fourteen patients with neuropathic pain (7 with unilateral foot pain due to peripheral nerve injury and 7 with bilateral pain in the feet due to distal polyneuropathy) underwent comprehensive characterization of somatosensory function by quantitative sensory testing. Patients were then administered an ultrasound-guided peripheral nerve block with lidocaine and intravenous lidocaine infusion in randomized order. The effect of these interventions on spontaneous pain intensity and on evoked cold, warm, pinprick, and brush responses was assessed at each session. All patients had sensory disturbances at baseline. The peripheral nerve block resulted in a complete abolition of ipsilateral pain within 10 min (median) in all patients, with lidocaine plasma concentrations being too low to account for a systemic effect of the drug. Intravenous lidocaine infusion reduced the spontaneous pain by 45.5% (±31.7%), and it reduced mechanical and thermal hypersensitivity in most patients who displayed such signs. However, the improvement in evoked hypersensitivity was not related to the effect of the drug on spontaneous pain intensity. This study demonstrated that regardless of the individual somatosensory phenotype and signs of central sensitization, primary afferent input is critical for maintaining neuropathic pain in peripheral nerve injury and distal polyneuropathy.